A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN17092, an YTE modified Anti-SARS-COV-2 (COVID-19) Monoclonal Antibody in Adult Healthy Volunteers

Authors
Category Primary study
ConferenceOpen forum infectious diseases
Year 2026
This article has no abstract
Epistemonikos ID: dee4ee567017b3a2d2ac22c13d0ace62131693e3
First added on: Mar 17, 2026